适用于2型糖尿病和慢性病患者的因克雷丁疗法
Radica Z Alicic1,2, Joshua J Neumiller1,3
1Providence Medical Research Center, Providence Inland Northwest Health, 105 W. 8th Ave, Suite 250E, Spokane, WA 99204, USA.
Journal of clinical medicine
|January 11, 2024
概括
类似葡萄糖类-1 (GLP-1) 受体激动剂在超出血糖控制的2型糖尿病 (T2D) 管理方面提供了显著的好处. 这些药物还可以保护心脏和脏,即使是在慢性脏病 (CKD) 患者中.
科学领域:
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 心脏病学 心脏病学
背景情况:
- 自2000年代初以来,新的降糖剂已经改变了2型糖尿病 (T2D) 治疗.
- 葡萄糖类-1 (GLP-1) 受体激动剂是T2D的关键治疗类.
- 这些药物提供了超出血糖控制的好处,包括心血管和脏保护.
研究的目的:
- 审查GLP-1受体激动剂在T2D管理中的既定和新兴益处.
- 要突出它们对心血管系统和脏的保护作用.
- 讨论它们在慢性病患者中的作用以及双GLP-1/GIP受体激动剂的潜力.
主要方法:
- 审查当前的科学文献和临床指导方针.
- 分析证据支持GLP-1受体激活剂的葡萄糖和非葡萄糖益处.
- 对患有CKD和心血管疾病的患者的GLP-1受体激活剂研究的审查.
主要成果:
- GLP-1受体激动剂减少心血管事件,并减缓慢性病 (CKD) 的进展.
- 它们的降糖效应在中度至重度的CKD中保持.
- 主要指南建议GLP-1受体激动剂用于T2D患者的CKD,肥胖或心血管风险.
结论:
- GLP-1受体激动剂对于管理T2D至关重要,提供显著的心脏保护和脏保护益处.
- 它们的疗效和安全性扩展到患有CKD的患者.
- 双GLP-1/GIP受体激动剂,如蒂尔泽帕提德,显示出有希望的结果,目前正在进行研究,以进一步定义它们在病中的作用.
相关概念视频
01:24Glucagon-like Receptor Agonists
325
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
325
01:23Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
204
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
204
01:06Oral Hypoglycemic Agents: Glinides
156
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
156
01:15Diabetes: Management and Pharmacotherapy
285
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
285
01:22Diabetes Mellitus: Type 2 and Gestational
2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K